Roche's Tecentriq excels in another lung cancer study
Months after securing FDA approval for Tecentriq as a first line of defense — in combination with chemotherapy — in extensive-stage small-cell lung cancer patients, Roche on Thursday said the immunotherapy helped certain treatment-naive patients with advanced non-small cell lung cancer (NSCLC) live longer versus chemotherapy, in a pivotal study.
The 572-patient trial, called IMpower110, tested Tecentriq monotherapy against chemotherapy (cisplatin or carboplatin and pemetrexed or gemcitabine) in patients with advanced non-squamous and squamous non-small cell lung cancer in patients without ALK or EGFR mutations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.